| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | CRB-913 Obesity (chronic weight management) — monotherapy and potential combination with incretin receptor agonists | Phase 1b | — | Subscribe to access the data. | Small Molecules | Endocrine System | |
Phase 1b data readout example | CRB-913 Obesity (chronic weight management) — monotherapy and potential combination with incretin receptor agonists | Phase 1b | — | Subscribe to access the data. | Small Molecules | Endocrine System | |
Phase 1b data readout example | CRB-913 Obesity (chronic weight management) — monotherapy and potential combination with incretin receptor agonists | Phase 1b | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Corbus Pharmaceuticals Holdings, Inc.
$11.14
-0.17 (-1.5%)
C 40Pipeline Score Overvalued Pharma · Clinical
Market Cap
208.37 M
EPS
-5.27
P/E Ratio
-
Value Trade
3.28 M
12.31 %
Week
23.57 %
1 Month
43.48 %
3 Month
44.4 %
6 Month
-77.88 %
5 Year
-87.39 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
271.59 K
52 Week Range
7.12 - 20.56
% held by Insiders
10.79 %
% held by Institutions
62.22 %
Enterprise Value
91.55 M
Total Shares
18.67 M
Short %
12.45 %
Float Shares
15.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corbus Pharmaceuticals Holdings, Inc.
768Total events
7Upcoming
96Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▲IND ClearanceCRB-701IND
Subscribe to view catalyst details
TBD
●Last Patient Last VisitCRB-913Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | CRB-913 | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-30 | CRB-913 | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-30 | CRB-913 | Phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
C40
Pipeline Score $94M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.5x
rNPV / MCap Top 63%
Micro Cap (rank 346 of 933)
Percentile RankCorbus Pharmaceuticals Holdings, Inc. carries a moderate pipeline score (40/100), with $832M risk-adjusted pipeline value, led by CRB-701 in Oropharyngeal Carcinoma (OPC) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRB-701 Small molecule | Oropharyngeal Carcinoma (OPC) | Phase 3 | NCT07768189 | 42% | $285M | NOT YET_RECRUITING | 260 | - | B (60) | Mar 1, 2029 | - | LOW Aug 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CRB-701 Fast Track | oropharyngeal and cervical cancers | Phase 1/2 | 2026-05-26 | oropharyngeal scc or: 42.9%; oropharyngeal scc dor: 6.3 months; oropharyngeal scc pfs: 5.6 months; cervical cancer or: 34.4%; cervical cancer dor: 8.0 months; cervical cancer pfs: 4.3 months; discontinuation rate: < 3% Read More | Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers Read More | |
CRB-701 Fast Track | oropharyngeal and cervical cancers | Phase 1/2 | 2026-05-26 | oropharyngeal scc or: 42.9%; oropharyngeal scc dor: 6.3 months; oropharyngeal scc pfs: 5.6 months; cervical cancer or: 34.4%; cervical cancer dor: 8.0 months; cervical cancer pfs: 4.3 months; discontinuation rate: < 3% Read More | Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers Read More | |
CRB-701 Fast Track | oropharyngeal and cervical cancers | Phase 1/2 | 2026-05-26 | oropharyngeal scc or: 42.9%; oropharyngeal scc dor: 6.3 months; oropharyngeal scc pfs: 5.6 months; cervical cancer or: 34.4%; cervical cancer dor: 8.0 months; cervical cancer pfs: 4.3 months; discontinuation rate: < 3% Read More | Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRBP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRBP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRBPCorbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals announced the grant of inducement equity awards to Leonardo Nicacio, who has joined as Chief Medical Officer. The grants include stock options and restricted stock units, aimed at incentivizing his employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting skilled professionals.
Read more →CRBPCorbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q2 2026 financial results, highlighting FDA clearance for the TEMPO-1 study of CRB-701 in oropharyngeal cancer, with enrollment set to begin in September 2026. The company also concluded the CANYON-1 Phase 1b study of CRB-913 for obesity, expecting data release in the same month. Additionally, Corbus announced key leadership appointments to enhance its strategic direction.
Read more →CRBP▲ +5.4%on this newsshared move
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has announced the completion of the last patient visit in its CANYON-1 Phase 1b trial for CRB-913, an oral CB1 inverse agonist aimed at treating obesity. The trial, which involved 240 participants, is set to provide topline data in September 2026. CRB-913 has shown a favorable gastrointestinal profile and potential for effective weight management compared to existing therapies.
Read more →CRBPCorbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals has received FDA clearance to start the TEMPO-1 registrational study for CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma. The study will evaluate CRB-701 against standard treatments and aims to support potential accelerated approval based on its efficacy. Approximately 14,000 patients are eligible for this treatment annually in the U.S.
Read more →CRBPCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals has appointed Dr. Leonardo Viana Nicacio as Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in oncology and drug development, notably in antibody drug conjugates. His appointment comes as Corbus prepares to initiate the TEMPO-1 study for CRB-701 in oropharyngeal squamous cell carcinoma, alongside other significant milestones in obesity treatment.
Read more →CRBP▼ -30.3%on this news
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Corbus Pharmaceuticals announced promising results from its Phase 1/2 study of CRB-701, showing significant efficacy in treating second-line oropharyngeal and cervical cancers. The confirmed objective response rates were 42.9% for oropharyngeal squamous cell carcinoma and 34.4% for cervical cancer. The drug was well tolerated, with low rates of treatment discontinuation. A registrational study is set to begin in summer 2026.
Read more →CRBP▲ +18.3%on this newsshared move
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Corbus Pharmaceuticals has appointed Nishant Saxena as Chief Business Officer and announced a conference call on May 26, 2026, to discuss updated data for its CRB-701 study. The data will be presented at the 2026 ASCO Annual Meeting, highlighting clinical responses in head and neck squamous cell carcinoma and cervical cancer. The company is advancing toward key milestones for its pipeline.
Read more →CRBPCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals has appointed Brent Pfeiffenberger to its Board of Directors. Pfeiffenberger, an experienced pharma leader, is expected to enhance Corbus's strategic direction, particularly for its clinical programs CRB-701 and CRB-913. The company anticipates important data readouts this summer and has aligned with the FDA on the registration path for CRB-701.
Read more →CRBP▲ +6.3%on this newsshared move
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc. has announced its participation in upcoming investor conferences, including the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference. CEO Yuval Cohen will present a corporate overview and engage in one-on-one investor meetings at these events. The company continues to focus on developing therapies for oncology and obesity, showcasing its commitment to innovative solution development in these areas.
Read more →CRBPCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q1 2026 financial results, highlighting significant progress in its oncology and obesity programs. The company has reached alignment with the FDA regarding the registration path for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. Additionally, Corbus completed enrollment in the CANYON-1 study for CRB-913, with topline data expected this summer.
Read more →CRBPCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Corbus Pharmaceuticals announced it will host a KOL event at the 2026 ASCO annual meeting to highlight new data from the Phase 1/2 clinical study of CRB-701. This study involves participants with head and neck squamous cell carcinoma and will be presented alongside subgroup analyses. The company recently aligned with the FDA regarding the registration path for CRB-701, indicating progress in its development. The event will feature insights from top oncology experts, facilitating a discussion on the findings.
Read more →CRBPCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Corbus Pharmaceuticals announced that updated clinical data for CRB-701 will be presented at the ASCO 2026 Annual Meeting. The data includes findings from a Phase 1/2 study focusing on head and neck squamous cell carcinoma and cervical cancer. The company plans to initiate a registrational study for CRB-701 in mid-2026 and anticipates further data releases later in the year.
Read more →CRBPCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will bui
Corbus Pharmaceuticals announced the enrollment of the last patient in the CANYON-1 Phase 1b clinical trial of CRB-913, an oral treatment for obesity. This 16-week study involves 240 participants and aims to explore dosing efficacy against obesity. Early Phase 1a results indicated nearly a 3% weight loss after 14 days, suggesting potential for CRB-913 as a new therapeutic option in obesity management. The company anticipates a successful data readout that may offer a promising alternative to existing treatments.
Read more →CRBPCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer FDA feedback enables Corbus to proceed with proposed registrational study design and end
Corbus Pharmaceuticals has announced significant progress in the development of its next-generation antibody drug conjugate, CRB-701, for treating head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The FDA has provided feedback that allows Corbus to proceed with its proposed registrational study designs, which could potentially lead to accelerated approval. Additionally, updated monotherapy data is expected to be presented at the upcoming ASCO 2026 Annual Meeting. Notably, Chief Medical Officer Dr. Dominic Smethurst will be leaving the company by June 30, 2026.
Read more →CRBP▼ -6%on this news
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals Holdings Inc. announced its participation in the BMO 2026 Metabolic Health Summit, where CEO Yuval Cohen will discuss advancements in metabolic disease treatment. The company is developing CRB-913, an innovative drug for obesity that has shown potential in recent clinical trials. A Phase 1b study for CRB-913 is ongoing, with results expected by summer 2026. This engagement at the summit demonstrates Corbus's active role in addressing metabolic health challenges and their commitment to advancing their clinical pipeline.
Read more →CRBP▲ +19.2%on this news
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q4 and 2025 financial results, highlighting promising data for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. The company also noted significant weight loss results from CRB-913, an obesity treatment. Despite a net loss of $20.6 million, a recent public offering has extended its cash runway into 2028. Key data readouts for both programs are anticipated in mid-2026.
Read more →CRBPThis presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Refor
Corbus's presentation outlines forward-looking statements regarding their pipeline and clinical trials for therapeutic candidates CRB-701, CRB-913, and CRB-601. The company highlighted the upcoming key clinical readouts for 2026 and mentioned the FDA Fast Track Designation for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. However, it cautioned that the predictions may be affected by various risks and uncertainties inherent in the biopharma industry. The efficacy and safety of CRB-701 relative to existing treatments such as PADCEV still require further validation through additional data.
Read more →CRBPCorbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
Corbus Pharmaceuticals Holdings Inc. will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. CEO Yuval Cohen will provide a corporate overview and participate in investor meetings. The conference will be held virtually, highlighting Corbus's commitment to innovative treatments in oncology and obesity.
Read more →CRBPCorbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Corbus Pharmaceuticals Holdings Inc. will present at the 2026 Annual J.P. Morgan Healthcare Conference. CEO Yuval Cohen will provide a corporate overview on January 15, 2026, at 8:15 a.m. PST. The company focuses on innovative treatments for oncology and obesity, with a promising pipeline of drug candidates.
Read more →CRBP▼ -5.7%on this news
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
Corbus Pharmaceuticals has completed a Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, showing a favorable safety profile and evidence of weight loss. The study involved both single and multiple ascending doses, with participants experiencing significant weight loss and no serious adverse events. A Phase 1b study is now underway, expected to conclude in summer 2026.
Read more →CRBPCorbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Corbus Pharmaceuticals is set to release results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist aimed at treating obesity, on December 11, 2025. This study includes single ascending and multiple ascending dose assessments. The company claims that CRB-913 has a lower brain penetration compared to other experimental drugs, which may reduce potential neuropsychiatric side effects. A conference call will follow the results announcement to discuss the data in detail.
Read more →CRBP▲ +7.4%on this news
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q3 2025 financial results, highlighting promising clinical data for CRB-701 presented at ESMO 2025. The company plans to meet with the FDA in early 2026 to discuss advancing CRB-701 for HNSCC and cervical cancer. Additionally, Corbus is progressing with CRB-913 for obesity treatment and has a robust cash position following a recent public offering.
Read more →CRBP▼ -26.1%on this news
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals has announced the pricing of a public offering of 4,744,231 shares at $13.00 each, alongside pre-funded warrants. The total offering size is around $75 million, which will be used for clinical development and general corporate purposes. The offering is expected to close on November 3, 2025, pending customary conditions.
Read more →CRBP▼ -26.1%on this newsshared move
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharmaceuticals has announced a proposed public offering of its common stock and pre-funded warrants. The proceeds will be used for clinical development and general corporate purposes. The offering is subject to market conditions, and the company has engaged Jefferies LLC and Piper Sandler as joint book-running managers. A registration statement has been filed with the SEC.
Read more →CRBP▼ -5.4%on this news
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Corbus Pharmaceuticals announced promising data from its Phase 1/2 study of CRB-701, targeting head and neck squamous cell carcinoma and cervical cancer. The study, presented at ESMO25, showed encouraging response rates among heavily pretreated patients. The company plans to meet with the FDA to discuss the data and potential registrational studies by mid-2026.
Read more →CRBPCorbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals announced the presentation of updated Phase 1/2 data for CRB-701 at the ESMO Congress 2025. The study includes 167 participants, with 122 evaluable for efficacy across various cancer types. A poster detailing safety and efficacy data will be presented, alongside a KOL event to discuss findings. CRB-701 has received Fast Track designations from the FDA.
Read more →CRBPCorbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
Corbus Pharmaceuticals announced its participation in the Piper Sandler Virtual Oncology Symposium, scheduled for October 9-10, 2025. CEO Yuval Cohen will engage in a Fireside Chat, providing insights into the company's innovative approaches in oncology and obesity. This event aims to enhance Corbus's visibility among investors and stakeholders.
Read more →CRBPCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
Corbus Pharmaceuticals will host an in-person and virtual KOL event during the ESMO Congress 2025 to discuss dose optimization data from its Phase 1/2 study of CRB-701. The event, featuring insights from leading experts, will take place on October 19, 2025, in Berlin. The study focuses on patients with advanced solid tumors expressing high levels of Nectin-4.
Read more →CRBP▲ +9.6%on this news· ran to +24% by day 1
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Corbus Pharmaceuticals has received Fast Track designation from the FDA for CRB-701, an antibody drug conjugate aimed at treating recurrent or metastatic head and neck squamous cell carcinoma. This designation is intended to expedite the development of drugs that address serious conditions. CRB-701 is currently undergoing a Phase 1/2 clinical trial to evaluate its safety and efficacy.
Read more →CRBP▲ +9.6%on this news· ran to +24% by day 1shared move
future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or
Corbus Pharmaceuticals has received Fast Track designation from the FDA for its drug CRB-701, intended to treat recurrent or metastatic head and neck squamous cell carcinoma. This designation is aimed at facilitating the development and review of important treatments that meet serious medical needs. The company plans to present dose optimization data from a Phase 1/2 study at ESMO 2025, as it continues to evaluate CRB-701's safety and efficacy. This marks the second Fast Track designation for CRB-701, following a previous designation for a different cancer indication in late 2024.
Read more →CRBPCorbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update • Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 • Initiat
Corbus Pharmaceuticals reported its financial results for Q2 2025, highlighting advancements in its clinical programs. The company is set to present Phase 1/2 expansion data for CRB-701 at the upcoming ESMO Congress and is on track for data readouts for all three clinical programs in the second half of 2025. Despite a net loss of approximately $17.7 million, they have received Fast Track designation from the FDA for CRB-701 and are advancing their obesity drug CRB-913 into later phases of study, aiming to minimize neuropsychiatric risks.
Read more →CRBPCorbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
Corbus Pharmaceuticals has announced that clinical data for its Nectin-4 targeting ADC, CRB-701, will be presented at the ESMO Annual Congress in October 2025. The presentation will include results from a Phase 1/2 study evaluating the drug's safety, pharmacokinetics, and efficacy in patients with advanced solid tumors. Part A of the study has been completed, and the company is currently conducting Part B and C, which focus on dose optimization and expansion. The event will showcase advancements in the usage of CRB-701 against tumors with high Nectin-4 expression.
Read more →CRBP▼ -6.8%on this news
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This follows the successful single ascending dose (SAD) study, which noted no treatment-related neuropsychiatric events. The MAD study, which focuses on assessing safety and pharmacokinetics, is scheduled for completion by Q3 2025. If successful, the company plans to start a Phase 1b dose-range finding study in obese individuals in late 2025.
Read more →CRBP▲ +8.9%on this newsshared move
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Corbus Pharmaceuticals has announced that the first patient has been dosed with CRB-701 in combination with pembrolizumab as part of a Phase 1 study focusing on advanced solid tumors. This milestone follows a successful review of the monotherapy cohort, with over 100 participants dosed thus far. The study aims to evaluate safety, pharmacokinetics, and efficacy, particularly targeting tumors with high Nectin-4 expression. Data updates and the recommended Phase 2 dose are expected later this year.
Read more →CRBPCorbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
Corbus Pharmaceuticals Holdings, Inc. announced its participation in the Piper Sandler 3rd Annual Virtual Obesity Symposium, scheduled for June 26, 2025. CEO Yuval Cohen will be involved in a fireside chat, alongside presentations from industry leaders. The company, known for its work in oncology and obesity, aims to address serious health issues through innovative therapies, including a pipeline of antibody drug conjugates and monoclonal antibodies. The event presents an opportunity for Corbus to showcase its expertise in obesity therapeutics.
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. announced that CEO Yuval Cohen will present a corporate update at the Jefferies Global Healthcare Conference on June 4, 2025. The conference will feature both a presentation and one-on-one investor meetings scheduled from June 3-5, 2025, in New York, NY. Corbus, a clinical-stage biotechnology company, is focused on developing innovative therapies for oncology and obesity, with a pipeline that includes several next-generation drug candidates. This event may enhance visibility among investors and promote stakeholder engagement.
Read more →CRBP▲ +5.7%on this newsshared move
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Corbus Pharmaceuticals has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, succeeding Alan Holmer. Jacques brings over 25 years of leadership experience in the biopharmaceutical industry and has been a member of the Corbus board for over six years. Under her leadership, the company anticipates critical clinical readouts from its pipeline of oncology and obesity drugs in the latter half of this year. The transition in leadership comes at a pivotal time as Corbus aims to address significant health challenges with its innovative therapies.
Read more →CRBP▲ +8.5%on this news
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. announced that its CEO, Dr. Yuval Cohen, will participate in the 2025 RBC Capital Markets Global Healthcare Conference in New York. The conference, scheduled for May 20-21, 2025, will feature a fireside chat and one-on-one meetings with investors. Corbus is focused on developing innovative therapies for oncology and obesity, with key products in its pipeline targeting critical biological pathways. The announcement underscores Corbus's commitment to engaging with the investment community and promoting its therapeutic advancements.
Read more →CRBP▼ -15.8%on this newsshared move
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update • Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in
Corbus Pharmaceuticals has reported its first quarter 2025 financial results, highlighting significant advancements in its product pipeline. The company is on track to complete dose optimization and recommended Phase 2 dose determination for CRB-701, its Nectin-4 ADC, by Q4 2025. Additionally, CRB-913, an anti-obesity drug, is scheduled to complete initial studies by Q3 2025. However, the company experienced a notable increase in net loss compared to the previous year, indicating financial challenges despite a strong cash position.
Read more →CRBPCorbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has announced the dosing of the first patient in the Phase 1 clinical study for its obesity treatment, CRB-913. This next-generation CB1 inverse agonist is designed to be more peripherally restricted than earlier drugs, aiming to enhance safety by reducing neuropsychiatric risks. The trial's single ascending dose/multiple ascending dose (SAD/MAD) phase is expected to conclude by Q3 2025, followed by a Phase 1b dose-range finding study in 2026. This milestone indicates progress in addressing significant needs in effective weight loss treatments.
Read more →CRBPAppendix 99.1 Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update • CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study • Fast T
Corbus Pharmaceuticals has reported its Q4 and 2024 financial results, highlighting progress in its oncology and obesity treatment pipelines. The company announced encouraging findings from its Phase 1 trial of CRB-701, an antibody drug conjugate targeting Nectin-4, which has received Fast Track designation from the FDA for treating metastatic cervical cancer. Financially, Corbus ended 2024 with $149 million in cash, sufficient to fund operations through Q3 2027. Additionally, the initiation of CRB-913’s Phase 1 study for obesity is expected in March 2025.
Read more →CRBPCorbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals has reported its financial results for Q4 and 2024, highlighting progress across its oncology and obesity pipelines. The company announced Fast Track Designation from the FDA for CRB-701, a drug targeting metastatic cervical cancer, alongside positive Phase 1 trial results showcasing safety and efficacy. Additionally, Corbus plans to initiate a Phase 1 study for CRB-913 in March 2025. Despite these advancements, financial reports indicate a net loss of $9.5 million for Q4, raising questions about the company's financial sustainability.
Read more →CRBP▼ -10.2%on this news
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 • Study mirrored 4 highest doses used in
Corbus Pharmaceuticals presented encouraging results for its CRB-701 (SYS6002), a next-generation Nectin-4 targeting ADC, at the ASCO-GU 2025 conference. The Phase 1 study conducted in the US and UK revealed a favorable safety profile with no dose-limiting toxicities and low levels of peripheral neuropathy and skin toxicity. Significant clinical responses were observed among participants with metastatic urothelial cancer and cervical cancer, as well as promising results for head and neck squamous cell carcinoma, which was previously unexplored. The dosing optimization is currently underway, indicating ongoing progress in the drug's development.
Read more →CRBP▼ -10.2%on this newsshared move
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
Corbus Pharmaceuticals has announced that the abstract for its CRB-701 dose escalation study will be presented at the 2025 ASCO-GU symposium. The study focuses on patients with advanced solid tumors with high Nectin-4 expression. The presentation will include updated clinical data from a total of 38 patients as of December 2024, expanding upon previous results from 31 patients. The three-part study aims to evaluate the safety and efficacy of CRB-701, a next-generation antibody-drug conjugate, in the U.S. and Europe.
Read more →CRBPCorbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
Corbus Pharmaceuticals Holdings, Inc. will be participating in the Guggenheim SMID Cap Biotech Conference on February 5-6, 2025. CEO Yuval Cohen will engage in a fireside chat and attend one-on-one meetings with investors. The company's pipeline includes innovative therapies aimed at oncology and obesity, showcasing their commitment to addressing serious health issues. The event presents an opportunity for Corbus to demonstrate its portfolio to analysts and potential investors.
Read more →CRBPCorbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
Corbus Pharmaceuticals announced that clinical data for CRB-701 from its Western dose escalation study will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in February 2025. This Phase 1 study evaluates the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors expressing high levels of Nectin-4. The company is implementing a three-part study design to establish optimized dosing and preliminary efficacy signals for this next-generation antibody-drug conjugate. CRB-701 aims to leverage Nectin-4 targeting in treating urothelial cancer and other solid tumors.
Read more →CRBPCorbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. announced that CEO Yuval Cohen will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 16, 2025. The conference will feature a presentation and one-on-one investor meetings. Corbus focuses on oncology and obesity therapies and is developing a pipeline of innovative treatments, including CRB-701 and CRB-601. The event aims to showcase the company's advancements and foster investor engagement.
Read more →CRBPCorbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Corbus Pharmaceuticals has announced the dosing of the first patient in its Phase 1 clinical study of CRB-601, a monoclonal antibody intended for the treatment of advanced solid tumors. The study aims to evaluate CRB-601's effectiveness in modulating TGFβ signaling and its potential to enhance the immune response against tumors. Pre-clinical data suggests that CRB-601 may boost the activity of immune checkpoint inhibitors. The company is hopeful this study will yield valuable insights into CRB-601's clinical potential.
Read more →CRBP▼ -6.1%on this news
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer Norwood, MA
Corbus Pharmaceuticals Holdings, Inc. has received Fast Track designation from the FDA for its next-generation antibody drug conjugate, CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer. The Fast Track status is intended to speed up the development and review process of promising drugs. Corbus has completed enrollment for the dose escalation phase of its Phase 1 clinical trial and expects to share initial data in Q1 2025. The company focuses on innovative treatments targeting well-understood biological pathways.
Read more →CRBPCorbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Corbus Pharmaceuticals Holdings, Inc. announced its participation in the 7th Annual Evercore HealthCONx Conference, scheduled for December 3-5, 2024, in Coral Gables, FL. CEO Yuval Cohen will engage in a fireside chat and hold one-on-one meetings with investors. The company focuses on developing innovative treatments for serious illnesses, featuring products such as CRB-701, CRB-601, and CRB-913 within its pipeline. This participation indicates Corbus's commitment to transparency and investor relations.
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. will participate in the Jefferies London Healthcare Conference from November 19-21, 2024. CEO Yuval Cohen is scheduled for a fireside chat and one-on-one investor meetings. The company focuses on oncology and obesity with a diverse portfolio of treatments, including a new antibody drug conjugate and monoclonal antibodies. This presentation aims to increase investor interest and showcase Corbus's scientific advancements.
Read more →CRBPCorbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its third quarter 2024 financial results, indicating a net loss of approximately $13.8 million. The company completed enrollment in the dose escalation part of a Phase 1 clinical trial for CRB-701, with initial data expected in Q1 2025. Additionally, positive pre-clinical data for CRB-913 was presented at Obesity Week 2024, with a Phase 1 trial planned to start in Q1 2025. The company has sufficient cash reserves projected to fund operations through Q3 2027.
Read more →CRBPCorbus Pharmaceuticals Reports 3 rd Quarter 2024 Financial Results and Provides a Corporate Update • Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting
Corbus Pharmaceuticals released its financial results for Q3 2024, reporting a net loss of approximately $13.8 million. The company completed enrollment for the dose escalation part of its Phase 1 clinical trial for CRB-701, targeting Nectin-4, with first data expected in Q1 2025. Additionally, they presented new pre-clinical data for CRB-913, aimed at obesity treatment, and are preparing to initiate a Phase 1 trial for this candidate in the same timeframe. The company anticipates these developments will strengthen its clinical pipeline moving forward.
Read more →CRBP▲ +8.2%on this newsshared move
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 • CRB-913 brain levels are 15-fold lower than monlunabant in lean mice • Dose-response demonstrated for a range of 5 to 80
Corbus Pharmaceuticals recently presented promising pre-clinical data for its obesity drug CRB-913 at Obesity Week 2024. The data indicates that CRB-913 reaches brain levels 15-fold lower than monlunabant while demonstrating a significant dose-dependent weight loss in diet-induced obese (DIO) mice. Notably, the study showed that CRB-913 can maintain weight loss even after discontinuation of semaglutide. The drug is on track to enter Phase 1 clinical trials in the first quarter of 2025.
Read more →CRBPCorbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Corbus Pharmaceuticals Holdings, Inc. has announced that its CEO, Yuval Cohen, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference from November 11-13, 2024. The conference will take place in Boston, MA, showcasing insights into the company's oncology and obesity drug developments. Corbus's portfolio includes key projects like CRB-701, CRB-601, and CRB-913, demonstrating its commitment to innovative treatments.
Read more →CRBPCorbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Corbus Pharmaceuticals has completed enrollment for the dose escalation part of its Phase 1 clinical trial for CRB-701, a novel antibody-drug conjugate targeting Nectin-4. The open-label trial, conducted in the US and UK, seeks to evaluate CRB-701's safety and efficacy in patients with advanced solid tumors. The first data from this study is anticipated in Q1 2025, and subsequent phases will optimize and expand dosing strategies. The study represents an important step in the development of CRB-701 as a potential treatment option in oncology.
Read more →CRBPCorbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
Corbus Pharmaceuticals will take part in the BMO Capital Markets Oncology Summit on October 8, 2024. The company’s Chief Medical Officer, Dr. Dominic Smethurst, will discuss strategies in oncology during a panel session. CEO Yuval Cohen will also engage in one-on-one investor meetings, emphasizing Corbus' active role in the oncology sector. The event marks an opportunity for Corbus to showcase its innovative pipeline and engage with investors.
Read more →CRBP▼ -8.3%on this news
Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
Corbus Pharmaceuticals Holdings, Inc. will present at the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York. CEO Yuval Cohen is set to participate in a fireside chat and one-on-one investor meetings. The company, focused on oncology, has a promising pipeline that includes innovative therapies targeting cancer and obesity. This presentation marks a strategic opportunity for Corbus to engage with investors and showcase its ongoing developments.
Read more →CRBPCorbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung Norwood, MA
Corbus Pharmaceuticals announced the appointment of Winston Kung to its Board of Directors, effective August 16, 2024. Kung, who will also chair the Audit Committee, comes with over 20 years of experience in life sciences and investment banking. His leadership is expected to provide valuable insights as Corbus advances its drug pipeline, which includes several promising therapies. Additionally, Avery Chip Catlin has resigned from the Board after ten years of service.
Read more →CRBPCorbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update • Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging effi
Corbus Pharmaceuticals has reported its second quarter 2024 financial results along with a corporate update featuring progress on its drug, CRB-701, for metastatic urothelial and cervical cancers. The clinical data presented at ASCO 2024 indicated encouraging efficacy and safety. The company has sufficient funds to sustain operations through Q3 2027. However, net losses have increased compared to the same period last year, raising some financial concerns.
Read more →CRBP▲ +7.1%on this news
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
Corbus Pharmaceuticals has announced the participation of CEO Yuval Cohen in two upcoming investor conferences in August. The conferences, BTIG Virtual Biotechnology Conference on August 5-6 and Wedbush PacGrow Healthcare Conference on August 13-14, will include corporate updates and one-on-one meetings with investors. The company's diverse pipeline includes innovative products targeting cancer and obesity, highlighting its commitment to advancing precision oncology and healthcare solutions.
Read more →CRBP▲ +9.4%on this news
SYS6002 (CRB-701) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at
Corbus Pharmaceuticals reported encouraging early results from the Phase 1 trial of SYS6002 (CRB-701), a next-generation antibody drug conjugate targeting Nectin-4. The latest data from 37 patients indicates a 44% overall response rate in metastatic urothelial cancer and 43% in cervical cancer, with minimal adverse events reported. Notably, no dose limiting toxicities have been observed at up to 4.5 mg/Kg doses. However, there were instances of skin rash and corneal disorders that require attention as the study progresses.
Read more →CRBPCorbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. will present at the 45th Annual Goldman Sachs Global Healthcare Conference from June 10-13, 2024, in Miami Beach, FL. CEO Yuval Cohen will provide a corporate update and engage in one-on-one investor meetings. The company is recognized for its innovative approach to precision oncology, highlighting its diverse pipeline, which includes promising drug candidates targeting cancer and obesity. This conference marks a significant opportunity for the company to showcase its advancements and attract potential investors.
Read more →CRBPCorbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference, scheduled for May 14-15, 2024. CEO Yuval Cohen will engage in a fireside chat and hold one-on-one meetings with investors. The company is recognized for its precision oncology focus, with a pipeline that includes promising drug candidates targeting advanced cancer treatments and obesity management.
Read more →CRBPCorbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on
Corbus Pharmaceuticals reported its financial results for Q1 2024, showcasing significant advancements within its pipeline, including the dosing of the first patient in the Phase 1 clinical trial of CRB-701. The company raised $116 million in capital, extending its cash runway through Q1 2027. Additionally, the data presented from early trials indicates promising safety and efficacy of CRB-701, targeting Nectin-4 in cancer treatment. The appointment of a new Chief Medical Officer further strengthens company leadership as it progresses towards key milestones.
Read more →CRBPCorbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Corbus Pharmaceuticals announced its participation in the BTIG Obesity Health Forum, scheduled for May 8, 2024. CEO Yuval Cohen will discuss CB1 Axis Therapies for Obesity during a panel session. The company's focus on innovative treatments, including pipeline products for obesity and cancer, underscores its commitment to addressing serious health issues. This engagement reflects Corbus's active role in industry dialogues related to advancements in therapeutic approaches.
Read more →CRBP▼ -5.8%on this news
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals has announced the acceptance of an abstract for presentation at the 2024 ASCO Annual Meeting, detailing updated data from the Phase 1 trial of CRB-701, a next-generation antibody-drug-conjugate. The trial, being carried out by partner CSPC in China, has shown promising safety and efficacy data. The abstract will be presented on June 1, 2024, emphasizing the significance of CRB-701 in targeting Nectin-4, a validated antigen in urothelial cancer. This presentation highlights Corbus's ongoing commitment to advancing treatments for serious illnesses.
Read more →CRBPCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals has dosed the first patient in its Phase 1 clinical trial of CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4. This trial aims to evaluate the safety, efficacy, and pharmacokinetics of the drug in patients with metastatic urothelial cancer and other tumors expressing high levels of Nectin-4. Encouraging data from an earlier Phase 1 study in China indicates that CRB-701 may have a differentiated profile compared to the existing treatment, PADCEV. The study is anticipated to contribute valuable insights into the potential benefits of CRB-701 for patients with advanced cancers.
Read more →CRBP▲ +16.5%on this news
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update • Encouraging CRB-701 (SYS6002) First-in Human Data Presented at ASCO-GU 2024; first patient expected
Corbus Pharmaceuticals announced its fourth quarter and year-end financial results for 2023, revealing a net loss of approximately $8.0 million. The company presented promising first-in-human data for CRB-701 at ASCO-GU 2024 and received FDA clearance for the IND application of CRB-601. Corbus has raised $116 million in funding, extending its financial runway to over three years. Additionally, the company appointed Dr. Dominic Smethurst as its new Chief Medical Officer.
Read more →CRBPCorbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Corbus Pharmaceuticals Holdings, Inc. will participate in the BMO Capital Markets Inaugural Obesity Summit on March 20, 2024. CEO Yuval Cohen, Ph.D., will join a panel discussion titled 'Emerging Therapeutics Landscape.' The company's participation highlights its focus on innovative treatments, particularly in the realm of obesity, where it is developing CRB-913, a CB1 inverse agonist.
Read more →CRBP▲ +7.4%on this news· ran to +39% by day 3
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals has appointed Dr. Dominic Smethurst as Chief Medical Officer, who will oversee the clinical development of its oncology drugs, including CRB-701 and CRB-601. Dr. Smethurst brings over twenty years of experience in biotechnology and pharmaceutical development. His immediate focus will include leading the upcoming US dose escalation study for CRB-701, which has demonstrated encouraging preliminary results. Corbus is positioned to advance its pipeline under Dr. Smethurst's leadership.
Read more →CRBPCorbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Corbus Pharmaceuticals Holdings, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. CEO Yuval Cohen will provide a corporate update and participate in one-on-one investor meetings. Corbus employs innovative approaches in precision oncology and is advancing several candidates in its pipeline, such as CRB-701 and CRB-913. The conference is a platform for the company to connect with investors and discuss its strategic directions moving forward.
Read more →CRBPForward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private
Corbus Pharmaceuticals has presented forward-looking statements regarding its clinical and regulatory strategies, restructuring, and product development timelines. The company's new Nectin-4 targeting ADC, CRB-701, is currently undergoing a phase 1 trial, which has completed several cohorts. Early results show an objective response rate of 43% and a disease control rate of 71%. However, there are inherent risks and uncertainties in the outcomes, as highlighted in the forward-looking statements provided by the company.
Read more →CRBPCorbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Corbus Pharmaceuticals has announced the successful closing of a public offering, which involved the sale of 4,973,750 shares of common stock, raising approximately $94.5 million. The shares were sold at a price of $19.00 each, reflecting strong investor interest. The offering included an additional 648,750 shares following the full exercise of the underwriters' option. Jefferies served as the sole book-running manager for this offering.
Read more →CRBP▲ +35.1%on this newsshared move
Corbus Pharmaceuticals Announces Proposed Public Offering Norwood, MA
Corbus Pharmaceuticals has announced a proposed public offering to sell shares of its common stock and pre-funded warrants. The company plans to use the net proceeds for clinical development and general corporate purposes. Jefferies will manage the offering, which is contingent on market conditions, and the specifics regarding the size and terms remain uncertain.
Read more →CRBP▲ +249.4%on this newsshared move
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 
Corbus Pharmaceuticals presented promising data for CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting nectin-4, at the ASCO-GU 2024 symposium. The Phase 1 study, which includes patients with metastatic urothelial cancer and other solid tumors, showed a 43% overall response rate and a 71% disease control rate. Importantly, there were no observed dose limiting toxicities, with manageable adverse events reported. The drug's ongoing dose escalation study highlights its potential as a treatment option for patients with nectin-4 positive tumors.
Read more →CRBPCorbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601) • CRB-601 is designed to block the activation of latent TGFβ in the tumor microen
Corbus Pharmaceuticals has received FDA clearance for its IND application for CRB-601, a monoclonal antibody designed to block the activation of latent TGF in the tumor microenvironment. The company plans to begin a Phase 1 clinical study in the first half of 2024, following promising pre-clinical data showing the drug's potential anti-tumor activity. This development underscores Corbus' commitment to advancing precision oncology therapies.
Read more →CRBPCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
Corbus Pharmaceuticals has announced that its Phase 1 clinical data for CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting nectin-4, has been accepted for presentation at the 2024 ASCO GU symposium in San Francisco. This presentation underscores the significance of CRB-701 in the context of treating urothelial cancer, a field with evolving therapeutic options. Notably, the data from a dose escalation study conducted in China highlights innovative approaches to cancer treatment.
Read more →CRBP▼ -16.7%on this news· ran to -36% by day 3
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update • Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early
Corbus Pharmaceuticals provided a corporate update and financial results for Q3 2023, reporting on advancements across its oncology pipeline. The company is set to release data from the CRB-701 dose escalation study in early 2024 and is preparing for the IND submission of CRB-601 later this year. Recent presentations at scientific conferences highlighted promising pre-clinical data for its products CRB-701 and CRB-913, indicating their potential in treating solid tumors and obesity, respectively. Despite progress, Corbus reported an increased net loss and rising operating expenses, reflecting ongoing financial challenges.
Read more →CRBPCorbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
Corbus Pharmaceuticals announced promising results from a pre-clinical study of CRB-913, a novel cannabinoid type-1 receptor inverse agonist, which demonstrated significant anti-obesity effects in a diet-induced obesity mouse model. The study showed enhanced weight loss and improvements in various metabolic parameters when CRB-913 was used in combination with incretin therapies like tirzepatide, semaglutide, or liraglutide. The results will be presented at the Obesity Week Conference, with further publication in the scientific journal Obesity scheduled for November. Corbus plans to advance CRB-913 to clinical trials to explore its potential in treating obesity and related conditions.
Read more →CRBPCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
Corbus Pharmaceuticals has presented the first pre-clinical characterization of CRB-701, a next generation ADC targeting nectin-4, at the AACR-NCI-EORTC conference. The data indicates that CRB-701 exhibits significant tumor growth inhibition in various preclinical models, showcasing a differentiated profile compared to similar therapies. Corbus plans to initiate its US clinical study for CRB-701 in Q1-2024, having shown initial success in dose escalation trials conducted in China. The drug features a novel site-specific conjugation chemistry aimed at improving patient outcomes.
Read more →CRBPCorbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
Corbus Pharmaceuticals is set to host a virtual 'Meet the Expert' session on CRB-701, a next-generation Nectin-4 antibody drug conjugate, on October 10, 2023. The event will feature insights from leading oncology specialists who will explore the drug's development and potential impact on various cancer indications. Discussion points will include defining unmet medical needs and differentiating CRB-701 from existing therapies like enfortumab vedotin. The panel aims to engage with the audience for a collaborative exchange of ideas and questions.
Read more →CRBPCorbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. cl
Corbus Pharmaceuticals reported encouraging advancements in its clinical trials, specifically highlighting the CRB-701 Phase 1 trial in China, which is ahead of schedule. The company plans to initiate a U.S. clinical trial for CRB-701 in Q1 2024, supported by promising preliminary pharmacokinetic data. Additionally, Corbus indicated that the IND submission for CRB-601 is expected by the end of Q4 2023, following successful pre-clinical presentations. However, the company faces financial challenges, reporting a net loss for the quarter.
Read more →CRBP▼ -12.4%on this news
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update • Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody dru
Corbus Pharmaceuticals announced its financial results for the first quarter of 2023, highlighting the expansion of its oncology pipeline through the in-licensing of CRB-701. The company is currently conducting a Phase 1 dose escalation study for CRB-701 in China and presented promising pre-clinical data for CRB-601 at AACR 2023. Financially, Corbus reported a higher net loss compared to the previous year due to increased operating expenses, while also confirming adequate funding through mid-2024. Dr. Yong Ben's appointment to the board is expected to enhance the company's strategic direction in oncology.
Read more →CRBP▼ -6.7%on this news· ran to -25% by day 3
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update • Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 anti
Corbus Pharmaceuticals has announced its financial results for Q4 2022, highlighting an expansion in its precision oncology pipeline with the licensing of CRB-701, a clinical-stage Nectin-4 antibody drug conjugate. The ongoing Phase 1 dose escalation for CRB-701 in China targets advanced solid tumors. Additionally, the company plans to submit an IND for CRB-601 in the second half of 2023, capitalizing on promising pre-clinical data. However, the financial report shows an increase in net loss and operating expenses, reflecting ongoing challenges in the current market environment.
Read more →CRBPCorbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA Norwood, MA
Corbus Pharmaceuticals has announced the appointment of Dr. Yong Ben, M.D., MBA, to its Board of Directors. Dr. Ben is an experienced oncology researcher and executive, known for leading various clinical development programs, including drug approvals. His background in healthcare venture investment complements Corbus' goals in precision oncology, particularly with their ongoing projects, CRB-701 and CRB-601. The company aims to leverage Dr. Ben's expertise to enhance its board and advance its promising pipeline.
Read more →CRBP▼ -11.1%on this news· ran to -33% by day 3
Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private
Corbus Pharmaceuticals has announced an exclusive licensing agreement with CSPC Pharmaceutical Group for its clinical-stage antibody drug conjugate, CRB-701, targeting Nectin-4 in various cancers. The agreement grants CSPC development rights in the US, Canada, Europe, and Australia, while also allowing Corbus to manage clinical development in these regions. Along with this partnership, Corbus will execute a 1-for-30 reverse stock split to comply with NASDAQ listing requirements. The partnership aims to leverage CSPC's capabilities and enhances Corbus's precision oncology pipeline.
Read more →CRBPCorbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update • Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Th
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update -Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022 -IND submission for CRB-601 is on track for mi
Read more →CRBP▼ -6.4%on this news
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors Norwood, MA
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors Norwood, MA, September 26, 2022 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), an immunology company, today announced the appointment of Anne Altmeyer, P
Read more →CRBPCorbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update • Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update -Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy -IND submission for CRB-601 is on track for
Read more →CRBPCorbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update • Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination w
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update -Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy -IND submission for CRB-601 is on-track for t
Read more →CRBP▼ -5.3%on this news
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting Norwood, MA
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting Norwood, MA, April 8, 2022 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), an immunology company, announce
Read more →CRBP▲ +7.1%on this news· ran to +26% by day 3
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates • Company is advancing its integrin program and on schedule for initiating clinical studies in 2023
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates -Company is advancing its integrin program and on schedule for initiating clinical studies in 2023 -Expanding immuno-oncology pipeline through strategic transactions
Read more →CRBPCorbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates  Company continues to advance integrin program from preclinical development toward the clinic  Expanding
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates Company continues to advance integrin program from preclinical development toward the clinic Expanding pipeline through strategic transactions remains key priority Cash and inves
Read more →CRBP▼ -5.3%on this news
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endo
Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinic Augmenting th
Read more →CRBPCorbus Pharmaceuticals Announces Topline Results from d eter m ine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28 Additional fi
Pharmaceuticals Announces Topline Results from determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis MA, June 24, 2021 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company developing innovati
Read more →CRBPCorbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGF
Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGF High potency anti- v 8 mAb licensed from University of Califor
Read more →CRBPCorbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of
Read more →CRBPCORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjour
Read more →CRBPCorbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannab
Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clini
Read more →CRBPCorbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen,
Read more →CRBPCorbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network Topline data expected in the
Read more →CRBPCorbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Topline data on schedule for Q2 2021 Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and Japan There is a significant need for safer and more effective treatments i
Read more →CRBPCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing in-house programs in me
Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with clinical
Read more →CRBPCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen
Read more →CRBPCorbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transf
Read more →CRBPCorbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceutica
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative m
Read more →CRBPCorbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent development
Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the se
Read more →CRBPCorbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
Topline data remain as previously reported Post-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background immunosuppressant therapies (greater than 2 years) Focusing on forced vital capac
Read more →CRBPCorbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformativ
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
As previously reported, lenabasum did not meet its primary efficacy endpoint in the study Lenabasum was well tolerated with no new safety findings Exploratory post-hoc analyses revealed unexpectedly low pulmonary exacerbation (PEx) rates in subjects from five eastern European c
Read more →CRBPCorbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE) Cannabinoid receptor type 2 expression is increased in lesional dermatomyositis skin compared to healthy skin
Read more →CRBPCorbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates Company is restructuring with the goal of extending cash runway to mid-2022 Workforce to be reduced by 54% Company to focus on compl
Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates Company is restructuring with the goal of extending cash runway to mid-2022 Workforce to be reduced by 54% Company to focus on completing Phase 3 dermatomyositis study and advancing preclinica
Read more →CRBPCorbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint Study did not meet primary endpoint of reducing rate of pulmonary exacerbations Lenabasum treatm
Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint MA, October 6, 2020 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering tran
Read more →CRBPCorbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis Topline data showed no significant differences in the primary and secondary endpoints when co
Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug ther
Read more →CRBPCorbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summer Phase 2b study of le
Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates MA, August 6, 2020 (GLOBE NEWSWIRE) -Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines th
Read more →CRBPCorbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants Topline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with characteristic skin and muscle involvement, serious morbidity, and increased
Read more →CRBPCorbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformati
Read more →CRBPCorbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per share Received $20 million first tranche fr
Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per share Received $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on
Read more →CRBPCorbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors Dr. Golumbeski formerly led corporate and business development at Celgene and Novartis Appointment adds unique skill set to Corbus Board ahe
Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors Dr. Golumbeski formerly led corporate and business development at Celgene and Novartis Appointment adds unique skill set to Corbus Board ahead of several key data readouts this summer MA, [July 8, 2020]-
Read more →CRBPCorbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label extension study ACR CRISS score at Week 52 is the primary endpoint in the RESOLVE-1 P
Read more →CRBPCorbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Topline data on schedule for Q3 2020 Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting therapies Treatment of inflammation to reduce PEx remains a key unmet need in CF Study
Read more →CRBPCorbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbations Study on target for data readout in late summer 2020 Norwood, MA, June 01, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“
Read more →CRBPCorbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Topline data on schedule for summer 2020 Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and Japan There are no FDA-approved therapies for the overall treatment of SSc Norwood, MA, May 27, 2020 (GLOB
Read more →CRBPCorbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activation Second abstract outlines baseline characteristics of RESOLVE-1 patients in EU Norwood, MA, May 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings,
Read more →CRBPCorbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b
Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remai
Read more →CRBPCorbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative
Read more →CRBPCorbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 study Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU
Read more →CRBPCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibros
Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis $46 million public offering in February 2020 to host conference call
Read more →CRBPCorbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director Norwood, MA
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director MA, March 10, 2020 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering tran
Read more →CRBPCorbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfo
Read more →CRBPCorbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the closing of it
Read more →CRBPCorbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Norwood, MA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the pricing of an
Read more →CRBPCorbus Pharmaceuticals Announces Proposed Public Offering of Common Stock Norwood, MA
Pharmaceuticals Announces Proposed Public Offering of Common Stock MA, February 6, 2020 - Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabin
Read more →CRBPCorbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medici
Read more →CRBPCorbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Company expects to report topline data from study in the summer of 2020 Primary endpoint of this study is reduction in pulmonary exacerbations Study enrolled participants regardless of CFTR mutation Stable background use of CFTR therapies was permitted Milestone advances Corb
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
- Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformati
Read more →CRBPCorbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious or severe AEs related to lenabasum reported in these studie
Read more →CRBPCorbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in s
Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020 Systemic sclerosis is a rare autoimmune disease
Read more →CRBPCorbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
- Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET - Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transform
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has the highest mortality rate among the systemic autoimmune di
Read more →CRBPCorbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis a
Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect 270,000 people total in U.S.
Read more →CRBPCorbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
- Company to host conference call and webcast on Thursday, August 8 at 8:30 a.m. ET - Norwood, MA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), today announced that the Company will host a conference call and
Read more →CRBPCorbus Pharmaceuticals to Host 2019 R&D Day in New York City
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that it will host a Research & Development Day (R&D Day) for
Read more →CRBPCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announce
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presented Presentation includes data from some systemic sclerosis subjects who have finished two years dosing with lenabasum Norw
Read more →CRBPCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
Norwood, MA, May 15, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announce
Read more →CRBPCorbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indicati
Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical can
Read more →CRBPCorbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Company anticipates topline results of RESOLVE-1 study in the summer of 2020 Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan SSc has the highest mortality rate among the systemic autoimmune
Read more →CRBPCorbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announce
Read more →CRBPCorbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
Phase 3 primary endpoint will now be aligned with that of previous Phase 2 study ACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current Phase 3 study Change in mRSS will become secondary endpoint No changes to conduc
Read more →CRBPCorbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors Appointment brings global commercialization and marketing experience for rare diseases to the Board of Directors Appointment aligns with Company's vi
Pharmaceuticals Appoints Rachelle Jacques to Board of Directors Appointment brings global commercialization and marketing experience for rare diseases to the Board of Directors Appointment aligns with Company's vision to become the leader in the treatment of inflammatory and
Read more →CRBPCORBUS CLASS ACTION NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. – CRBP
NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from November 14, 2016 through February
Read more →CRBPCorbus Pharmaceuticals Provides Management Team Updates
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operations Sergei Atamas, M.D., Ph.D., appointed as Executive Director of Research to lead drug discovery Leadersh
Read more →CRBPCORBUS PHARMACEUTICALS HOLDINGS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Corbus Pharmaceuticals Holdings, Inc.
NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (Nasdaq: CRBP) in the United States Distric
Read more →CRBPCorbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inf
Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoi
Read more →CRBPCorbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s lea
Read more →CRBPCorbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s le
Read more →CRBPCorbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021 Mr. Millian previously held positions at EMD Serono, Vertex, Pfizer and Sanofi Com
Read more →CRBPCorbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Norwood, MA, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases through the endoca
Read more →CRBPCorbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis Collaboration in-line with Corbus vi
Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammato
Read more →CRBPCorbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system Lenabasum in late-stage clinical studies in three orphan indications with combined 350,000 patients in the US, EU and Japan Issuance of compos
Read more →CRBPCorbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare autoimmune diseases Lenabasum has Orphan Drug Designation for treatment of DM i
Read more →CRBPCorbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update Licensed Jenrin Discovery's extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Cor
Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update Licensed Jenrin Discovery's extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory a
Read more →CRBPCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with live audio webcast on Wednesday, November 28 at 4:00 p.m. EST – Norwood, MA, Nov. 0
Read more →CRBPCorbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
- Company to host conference call and webcast on Nov. 8th at 8:30 AM ET - Norwood, MA, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s leading pipeli
Read more →CRBPCorbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseases Favorable safety and tolerability profiles maintained with long-term chronic dosing Further improvement in key efficacy outcomes shows strength and durability of
Read more →CRBPCorbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediators in airway macrophages from cystic fibrosis patients Cystic fibrosis is a life-threatening rare genetic disease that affects ~30,000 patients in the U.S. and ~70,000 patients
Read more →CRBPCorbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system Intellectual property around pipeline targeting endocannabinoid system now covers lenabasum and CRB-4001 Lenabasum is in late-stage clinical s
Read more →CRBPCorbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat and live audio webcast on Tuesday, October 2nd at 3:00 PM ET – Norwood, MA , Sept. 26, 2
Read more →CRBPCorbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
Management to host conference call and webcast this morning at 8:30 a.m. EDT Jenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with small molecules specifically designed to target the endocannabinoid system Pipeli
Read more →CRBPCorbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high as 30% Norwood, MA, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals H
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical c
Read more →CRBPCorbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serio
Read more →CRBPCorbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update - Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositi
Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update - Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan - R
Read more →CRBPCorbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months 12-month 150 subject study with ACR/EULAR 2016 Total Improvement Score in myositis as primary efficacy outcome Approximately 80,000 d
Read more →CRBPCorbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high as 30% Norwood, MA, July 20, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Ho
Read more →CRBPCorbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms Norwood, MA and New York, NY, June 21, 2018 (GLOBE NEWSWIRE) -- Corbus P
Read more →CRBPCorbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
- Live fireside chat webcast on Wednesday, June 20th at 2:30 p.m. EDT - Norwood, MA, June 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and
Read more →CRBPCorbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018 Multiple key efficacy outcomes further improved in open-labe
Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018 Multiple key efficacy outcomes further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (D
Read more →CRBPCorbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of Directors as Company enters late-stage clinical development – Norwood, MA, June
Read more →CRBPCONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors - Distinguished 25-year career serving at the U.S. Food an
DRAFT NOT FOR IMMEDIATE RELEASE Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER Appoin
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the developm
Read more →CRBPCorbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”),
Read more →CRBPCorbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented - Norwood, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or
Read more →CRBPCorbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update - Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and ser
Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases - MA (May 10, 2018) - Corb
Read more →CRBPCorbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
NORWOOD, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.
Read more →CRBPCorbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update Advancing clinical studies in four rare and serious inflammatory diseases with significant morbidity and mortality and clear unmet medica
Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update Advancing clinical studies in four rare and serious inflammatory diseases with significant morbidity and mortality and clear unmet medical needs Reported positive data in Phase 2 dermatomyositis clin
Read more →CRBPCorbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
NORWOOD, MA--(Marketwired - March 02, 2018) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.,
Read more →CRBPCorbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
NORWOOD, MA--(Marketwired - February 15, 2018) - Study identifies lenabasum as important upstream trigger of resolution of innate immune responses Data provides mechanistic validation of positive clinical data reported from Company's Phase 2 clinical studies in systemic scleros
Read more →CRBPCorbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
NORWOOD, MA--(Marketwired - February 14, 2018) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D
Read more →CRBPCorbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
NORWOOD, MA--(Marketwired - February 06, 2018) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D
Read more →CRBPCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
NORWOOD, MA--(Marketwired - January 30, 2018) - Award will support ~415-patient, 6-month Phase 2b study designed to provide clear evidence of clinical benefit for people with CF Event rate of pulmonary exacerbations is sole primary efficacy endpoint of study Pulmonary exacerba
Read more →CRBPCorbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
NORWOOD, MA--(Marketwired - January 29, 2018) - Multi-national Phase 2b is designed to provide clear evidence of clinical benefit of lenabasum (formerly known as anabasum) in patients with CF Study will enroll ~415 participants with CF 12 years of age and older regardless of un
Read more →CRBPCorbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
NORWOOD, MA--(Marketwired - December 22, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting chronic, serious inflammatory and fibrotic diseases, announced today the initiation of a Phase 2
Read more →CRBPCorbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
NORWOOD, MA--(Marketwired - December 14, 2017) - Systemic sclerosis is a rare, serious chronic autoimmune disease with no approved therapy Affects approximately 90,000 individuals in US and EU and associated with 10-year mortality of 40-60% Corbus Pharmaceuticals Holdings, Inc
Read more →CRBPCorbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
NORWOOD, MA--(Marketwired - November 27, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent a
Read more →CRBPCorbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering Norwood, MA (
Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering MA (November 27, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chro
Read more →CRBPCorbus Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
NORWOOD, MA--(Marketwired - November 15, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D
Read more →CRBPCorbus Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
NORWOOD, MA--(Marketwired - November 09, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D
Read more →CRBPCorbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements Positive data from three consecutive Phase 2 studies in rare and serious chronic inflammatory
Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements Positive data from three consecutive Phase 2 studies in rare and serious chronic inflammatory and fibrotic diseases provides validation of anabasum's unique a
Read more →CRBPCorbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study
NORWOOD, MA--(Marketwired - November 06, 2017) - Systemic sclerosis is a rare autoimmune disease with no approved therapies, affecting 90,000 individuals in US and EU with a 10-year mortality rate of 35-50% Anabasum achieved reduction in mRSS of 8.4 points from start of study (
Read more →CRBPCorbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases
NORWOOD, MA--(Marketwired - October 31, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent an
Read more →CRBPCorbus Pharmaceuticals Holdings, Inc. Prices Underwritten Public Offering of Common Stock
NORWOOD, MA--(Marketwired - October 24, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced the pricing of a $32.5
Read more →CRBPCorbus Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering of Common Stock Norwood, MA (
Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering of Common Stock MA (October 23, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory an
Read more →CRBPCorbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis - Data selected for late-breaking presentation at ACR on
Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis Data selected for late-breaking presentation at ACR on November 7, 2017 - Anabasum improved CDASI activity score by 9.3 points vs 3.7 for placebo at end of study (p =
Read more →CRBPCorbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors Norwood, MA (
Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of MA (October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference
NORWOOD, MA--(Marketwired - September 25, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will present
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting
NORWOOD, MA--(Marketwired - September 20, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts ha
Read more →CRBPCorbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
NORWOOD, MA--(Marketwired - September 14, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.
Read more →CRBPCorbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD
NORWOOD, MA--(Marketwired - August 31, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will host a live
Read more →CRBPCorbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update - Data from Phase 2 open-label extension study of anabasum for the treatment of systemic sclerosis expected in Q4 2017 - -
Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update Data from Phase 2 open-label extension study of anabasum for the treatment of systemic sclerosis expected in Q4 2017 - Phase 3 study of anabasum for the treatment of system sclerosis expe
Read more →CRBPCorbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research
NORWOOD, MA--(Marketwired - August 07, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed s
Read more →CRBPCorbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index
NORWOOD, MA--(Marketwired - June 26, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it was added to the R
Read more →CRBPCorbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting
NORWOOD, MA--(Marketwired - June 15, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that safety and efficacy d
Read more →CRBPCorbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
NORWOOD, MA--(Marketwired - June 08, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that safety, pharmacokinet
Read more →CRBPCorbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference
NORWOOD, MA--(Marketwired - June 01, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today, Yuval Cohen, Ph.D., Chief
Read more →CRBPCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
NORWOOD, MA--(Marketwired - May 11, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that subject enrollment is
Read more →CRBPCorbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update - Q1 2017 marked by positive data from Phase 2 study of anabasum for the treatment of cystic fibrosis - - Company ended the
Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update Q1 2017 marked by positive data from Phase 2 study of anabasum for the treatment of cystic fibrosis - Company ended the quarter with $49 million of cash which is sufficient to fund operati
Read more →CRBPCorbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
NORWOOD, MA--(Marketwired - April 05, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that the Company will be
Read more →CRBPCorbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis - Anabasum achieves
Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis Anabasum achieves primary study objective of acceptable safety and tolerability - Management to
Read more →CRBPCorbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update - Q4 2016 marked by positive data from Phase 2 study of JBT-101 for the treatment of systemic sclerosis showing clear signal of clin
Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update Q4 2016 marked by positive data from Phase 2 study of JBT-101 for the treatment of systemic sclerosis showing clear signal of Topline data for Phase 2 cystic fibrosis study expected to be reported
Read more →CRBPCorbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
NORWOOD, MA--(Marketwired - March 08, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield
Read more →CRBPCorbus Pharmaceuticals Completes $27.2 Million Registered Direct Offering
NORWOOD, MA--(Marketwired - March 03, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today the completion of the Com
Read more →CRBPCorbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
NORWOOD, MA--(Marketwired - March 01, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.,
Read more →CRBPCorbus Pharmaceuticals Announces $27.2 Million Registered Direct Offering Norwood, MA (
Pharmaceuticals Announces $27.2 Million Registered Direct Offering MA (February 28, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic di
Read more →CRBPCorbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
NORWOOD, MA--(Marketwired - February 23, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles,
Read more →CRBPCorbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
NORWOOD, MA--(Marketwired - February 21, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that it will host its
Read more →CRBPCorbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
NORWOOD, MA--(Marketwired - January 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commi
Read more →CRBPCorbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - December 29, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed
Read more →CRBPCorbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony
NORWOOD, MA--(Marketwired - December 05, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D
Read more →CRBPCorbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases will visit the Nasdaq MarketSite in Times Square. In honor of the occas
Read more →CRBPCorbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
NORWOOD, MA--(Marketwired - November 29, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it is commencing
Read more →CRBPCorbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis Difference in CRISS scores over trial period between JBT-101
Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis Difference in CRISS scores over trial period between JBT-101 and placebo groups was significant (p = 0.044) Median CR
Read more →CRBPCorbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update - Topline data for Phase 2 study of systemic sclerosis on track to be reported in fourth quarter of 2016 - - Topline data f
Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update Topline data for Phase 2 study of systemic sclerosis on track to be reported in fourth quarter of 2016 - Topline data for Phase 2 study of cystic fibrosis on track to be reported in first
Read more →CRBPCorbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
NORWOOD, MA--(Marketwired - October 18, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commi
Read more →CRBPCorbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
NORWOOD, MA--(Marketwired - October 13, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed t
Read more →CRBPCorbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
NORWOOD, MA--(Marketwired - September 28, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced today that Professor Der
Read more →CRBPCorbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit
NORWOOD, MA--(Marketwired - September 19, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.
Read more →CRBPCorbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - September 12, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed
Read more →CRBPCorbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update - On track to complete Phase 2 studies in systemic sclerosis and cystic fibrosis in fourth quarter of 2016 - Norwood, MA (
Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update On track to complete Phase 2 studies in systemic sclerosis and cystic fibrosis in fourth quarter of 2016 - MA (August 15, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Co
Read more →CRBPCorbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016
NORWOOD, MA--(Marketwired - July 06, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., C
Read more →CRBPCorbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
NORWOOD, MA--(Marketwired - June 17, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., C
Read more →CRBPThis presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assum
TARGETING THE IMMUNE SYSTEM IN RARE DISEASES NASDAQ:CRBP | CORBUSPHARMA.COM EXHIBIT 99.1 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competiti
Read more →CRBPCorbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
NORWOOD, MA--(Marketwired - June 16, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed pati
Read more →CRBPCorbus Pharmaceuticals Completes $15 Million Registered Direct Offering
NORWOOD, MA--(Marketwired - June 15, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today the completion of the Comp
Read more →CRBPCorbus Pharmaceuticals Announces $15 Million Registered Direct Offering Norwood, MA (
Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering Norwood, MA (June 10, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fi
Read more →CRBPCorbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update - Company has Three Phase 2 Studies Ongoing with Top-Line Data Expected Starting 4Q 2016 - - Phase 2 Clinical Study for Tre
Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update Company has Three Phase 2 Studies Ongoing with Top-Line Data Expected Starting 4Q 2016 - Phase 2 Clinical Study for Treatment of Systemic Lupus Erythematosus Expected to Commence 1Q 2017 -
Read more →CRBPCorbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
NORWOOD, MA--(Marketwired - April 12, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Food and D
Read more →CRBPCorbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
NORWOOD, MA--(Marketwired - March 31, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that a protocol amendme
Read more →CRBPCorbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update - 2015 Marked by Significant Momentum on the Operational, Clinical and Regulatory Fronts and Builds Solid Foundation for an Importan
Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update - 2015 Marked by Significant Momentum on the Operational, Clinical and Regulatory Fronts and Builds Solid Foundation for an Important Year Ahead - - Top-line Data Expected in Three Phase 2 S
Read more →CRBPCorbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
NORWOOD, MA--(Marketwired - Mar 7, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Resunab will be tes
Read more →CRBPCorbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
NORWOOD, MA--(Marketwired - Feb 1, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.,
Read more →CRBPCorbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
NORWOOD, MA--(Marketwired - Jan 5, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.,
Read more →CRBPCorbus Pharmaceuticals Reports 2015 Third Quarter Financial Results - Company Launched Three Separate Phase 2 Studies with Top-line Data Expected Starting at the End of 2016 - - U.S. Orphan Drug and Fast Track Designatio
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results - Company Launched Three Separate Phase 2 Studies with Top-line Data Expected Starting at the End of 2016 - - U.S. Orphan Drug and Fast Track Designations Granted for Resunab for both Cystic Fibrosis and System
Read more →CRBPCorbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - Oct 20, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and
Read more →CRBPCorbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - Oct 15, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the first subject
Read more →CRBPCorbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
NORWOOD, MA--(Marketwired - Oct 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the Company's Chie
Read more →CRBPCorbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
NORWOOD, MA--(Marketwired - Oct 7, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the first subject w
Read more →CRBPCorbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis
NORWOOD, MA--(Marketwired - Sep 22, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that it will present ad
Read more →CRBPCorbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - Sep 21, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that patient enrollment
Read more →CRBPCorbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis
NORWOOD, MA--(Marketwired - Aug 31, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that patient enrollment
Read more →CRBPCorbus Pharmaceuticals Successfully Completes Warrant Call - Raises $11.3 mm in Total from 100% Exercise of CallableWarrants Proceeds to fund Resunab Phase 2 studies in cystic fibrosis, systemic sclerosis and dermatomyos
Corbus Pharmaceuticals Successfully Completes Warrant Call - Raises $11.3 mm in Total from 100% Exercise of CallableWarrants Proceeds to fund Resunab Phase 2 studies in cystic fibrosis, systemic sclerosis and dermatomyositis Company has $14.2 million of cash together with $3.8
Read more →CRBPCorbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
NORWOOD, MA--(Marketwired - Aug 19, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and
Read more →CRBPCorbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update Norwood, MA (
Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update Norwood, MA (August 13, 2015) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), a clinical stage drug development company targeting rare, chronic, and
Read more →CRBPCorbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
NORWOOD, MA--(Marketwired - Aug 6, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.,
Read more →CRBPCorbus Pharmaceuticals Announces Call Notice for Exercise of Warrants - Use of proceeds to advance Phase 2 clinical studies - Norwood, MA (
Corbus Pharmaceuticals Announces Call Notice for Exercise of Warrants - Use of proceeds to advance Phase 2 clinical studies - Norwood, MA (July 27, 2015) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ( Corbus or the Company ), a clinical stage pharmaceutical company tar
Read more →CRBPCorbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis
NORWOOD, MA--(Marketwired - Jul 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that patient dosing has
Read more →CRBPCorbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 23, 2015
NORWOOD, MA--(Marketwired - Jun 17, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D.
Read more →CRBPCorbus Pharmaceuticals Announces Inclusion in Russell MicroCap(R) Index
NORWOOD, MA--(Marketwired - Jun 16, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that it will be added t
Read more →CRBPCorbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)
NORWOOD, MA--(Marketwired - Jun 12, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and
Read more →CRBPCorbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
NORWOOD, MA--(Marketwired - Jun 5, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that its Phase 2 clinica
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference
NORWOOD, MA--(Marketwired - Jun 1, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that positive data on th
Read more →CRBPCorbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
NORWOOD, MA--(Marketwired - May 18, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today that its Investigat
Read more →CRBPCorbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board
NORWOOD, MA--(Marketwired - May 14, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the "Company"), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today that it has appointed Charles N
Read more →CRBPCorbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update -First quarter marked by significant progress on operational, clinical and regulatory milestones- -Company expects to comme
Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update -First quarter marked by significant progress on operational, clinical and regulatory milestones- -Company expects to commence Phase 2 clinical studies of Resunab in scleroderma in
Read more →CRBPCorbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015
NORWOOD, MA--(Marketwired - May 4, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the Company), a clinical stage drug development company targeting rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive O
Read more →CRBPCorbus Pharmaceuticals Receives $5 Million Development Award from Cystic Fibrosis Foundation Therapeutics to Advance Resunab Clinical Program - Award Supports Initiation of Phase 2 Clinical Trial with Resunab, a Novel Or
Corbus Pharmaceuticals Receives $5 Million Development Award from Cystic Fibrosis Foundation Therapeutics to Advance Resunab Clinical Program - Award Supports Initiation of Phase 2 Clinical Trial with Resunab, a Novel Oral Anti-Inflammatory and Anti-Fibrotic Drug, in Individu
Read more →CRBPCorbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
NORWOOD, MA--(Marketwired - Apr 16, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company focused on the development and commercialization of treatments for rare, life-threatening inflammatory and fibrotic diseases, announced that
Read more →CRBPCorbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
NORWOOD, MA--(Marketwired - Apr 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab, for the treatment of rare, life-threatening
Read more →CRBPCorbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab(TM) in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
NORWOOD, MA--(Marketwired - Apr 1, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that positive pre-clinica
Read more →CRBPCorbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab(TM)
NORWOOD, MA--(Marketwired - Mar 9, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), announced today that company's Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and it is authorized to initiate a Ph
Read more →CRBPCorbus Pharmaceuticals Observes Annual Rare Disease Day
NORWOOD, MA--(Marketwired - Feb 27, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threaten
Read more →CRBPCorbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
NORWOOD, MA--(Marketwired - Feb 11, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threaten
Read more →CRBPCorbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update Norwood, MA (
Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update Norwood, MA (February 10, 2015) Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company ), an emerging drug development company focused on the development and commercialization of i
Read more →CRBPForward Looking Statements This presentation contains certain forward looking statements, including those relating to the Company s product development, clinical and regulatory timelines, market opportunity, competitive
Case Western Reserve Medical School Professor Medicine, National PI on largest ever anti inflammatory CF study Robert Spiera M.D. Hospital for Special Surgery NYC Professor of Medicine, Head of Scleroderma and Vasculitis Center Daniel Furst, M.D. UCLA School of Medicine Director
Read more →CRBPCorbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
NORWOOD, MA--(Marketwired - Feb 2, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threateni
Read more →CRBPCorbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
NORWOOD, MA--(Marketwired - Dec 3, 2014) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threateni
Read more →CRBPCorbus Pharmaceuticals Reports 2014 Third Quarter Results and Business Update Norwood, MA (
Corbus Pharmaceuticals Reports 2014 Third Quarter Results and Business Update Norwood, MA (November 13, 2014) Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company ), an emerging growth drug development company focused on the development and commercialization of its
Read more →CRBPForward Looking Statement 2 This presentation contains certain forward looking statements, including those relating to the Company s product development, clinical and regulatory timelines, market opportunity, competitive
Vertex Kalydeco Cystic Fibrosis mutations of CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R $294,000 $1.2B** * Figures from company press releases ** Leerink analyst report Market Cap of CF and Fibrosis Focused Companies 24 $286 $685 $1,347 $5,335
Read more →CRBPCorbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP
NORWOOD, MA--(Marketwired - Oct 28, 2014) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threatening inflammatory
Read more →CRBPCorbus Pharmaceuticals to Present at the 13th Annual BIO Investor Forum in San Francisco on Wednesday, October 8, 2014
NORWOOD, MA--(Marketwired - Oct 1, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab -- for the treatment of rare, life-threatening inflammatory diseases -- a
Read more →CRBPCorbus Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014
NORWOOD, MA--(Marketwired - Sep 30, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab -- for the treatment of rare, life-threatening inflammatory diseases --
Read more →CRBPCorbus Pharmaceuticals to Present at Two Investor Conferences in September
NORWOOD, MA--(Marketwired - Sep 4, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare, life-threatening inflammatory diseases, anno
Read more →CRBPCorbus Pharmaceuticals Observes World Scleroderma Day
NORWOOD, MA--(Marketwired - Jun 26, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare ("orphan") life-threatening inflammatory dis
Read more →CRBPCorbus Pharmaceuticals to Present at the 2014 BIO International Convention
NORWOOD, MA--(Marketwired - Jun 16, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare ("orphan") life-threatening inflammatory dis
Read more →CRBPCorbus Pharmaceuticals Completes $10.3 Million Private Placement
NORWOOD, MA--(Marketwired - Jun 3, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab , for the treatment of rare ("orphan") life-threatening inflammatory dise
Read more →Competitive Position
How CRBP ranks across every disease it competes inCompetitive Position is a premium feature
See how CRBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial